Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S9910||SWOG||Leukemia Centralized Reference Laboratories and Tissue Repositories Ancillary||Adult CIRB - Late Phase Emphasis||Completed|
|S1608||SWOG||Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1929||SWOG||Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA6134||ECOG-ACRIN||A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|LungMAP||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011502||Alliance||A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5152||ECOG-ACRIN||A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-BN007||NRG||A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylganine DNA Methyltransferase) Unmethylated Glioblastoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|CALGB-49808||CALGB||A 2 X 2 X 2 Factorial Randomized Phase III Trial of Multimodality Therapy Comparing 4 Cycles of Doxorubicin and Cyclophosphamide with or without Dexrazoxane (AC +/- Z) Followed by 12 Weeks of Weekly Paclitaxel with or without Trastuzumab (T H) Followed by Local Therapy Followed by 40 Weeks of Weekly Trastuzumab or none in Women with HER-2+ STAGE IIIA; IIIB or Regional Stage IV Breast Cancer **ADMINISTRATIVELY COMPLETED as of December 15; 2002**||Adult CIRB - Late Phase Emphasis||Completed|
|N0147||NCCTG||A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|